Intracellular mGluR5 Can Mediate Synaptic Plasticity in the Hippocampus

While metabotropic glutamate receptors (mGluRs) are typically viewed as cell-surface switches, research has shown that mGluR5 can also reside on intracellular membranes, such as the endoplasmic reticulum and nuclear envelope. This study sought to determine if this intracellular pool of mGluR5 is functional in hippocampal CA1 pyramidal neurons and whether it contributes to synaptic plasticity, such as long-term potentiation (LTP) and long-term depression (LTD).

Researchers used a combination of dissociated rat hippocampal CA1 cultures and acute slice preparations. They utilized pharmacological tools—specifically impermeable, nontransported ligands like the antagonist LY53 and the agonist DHPG—to selectively isolate cell-surface versus intracellular receptor populations. They also employed glutamate uncaging to activate receptors in specific dendritic locations and examined synaptic plasticity in both wild-type and mGluR5-knockout mice to confirm receptor dependency.

The authors found that mGluR5 is abundant on both cell-surface and intracellular membranes in hippocampal neurons. Pharmacological separation revealed that while both pools can trigger calcium oscillations, intracellular mGluR5 activation produces sustained, high-amplitude calcium rises in dendrites, distinct from surface-mediated responses. Crucially, while cell-surface mGluR5 is necessary for LTP, intracellular mGluR5 activation alone is sufficient to mediate LTD. Furthermore, this intracellular-mediated LTD is protein synthesis-dependent, matching the known characteristics of classic hippocampal mGluR-LTD.

mGluR5 is a key therapeutic target for neurodevelopmental and psychiatric disorders, including fragile X syndrome and schizophrenia. This research reveals that current drug strategies, which often target cell-surface receptors, may be incomplete or missing a significant component of receptor signaling. Understanding that intracellular pools of mGluR5 drive specific forms of synaptic plasticity opens new possibilities for designing drugs with increased specificity to modulate particular signaling pathways.